전문정보검색
| No | 제목 / 내용 |
|---|---|
| 1 |
Journal of the Chemical Society, Perkin Transactions 1 |
| 2 |
Philosophical Magazine Series 1 |
| 3 |
Lettere Al Nuovo Cimento Series 1 |
| 4 |
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Adult, Antibodies, Monoclonal, adverse effects, pharmacology, therapeutic use, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung |
| 5 |
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. To unravel |
| 6 |
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Adenocarcinoma, drug therapy, genetics, secondary, Adult, Aged, Antibodies, Monoclonal, Humanized, adverse effects, therapeutic use, |
| 7 |
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Coronavirus Infections, Pandemics, Humans, physiology, Half-Life, Microbial Viability, COVID-19, pathogenicity, SARS Virus, SARS-CoV |
| 8 |
Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin Glucagon-like peptide 1 (GLP-1) stimulated insulin secretion has a considerable heritable component as estimated from twin studies, ye |
| 9 |
Targeting HIF-1 for cancer therapy. Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biology, includ |
| 10 |
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma Preclinical studies suggest that Reed–Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In cl |